1 We gave treatment
open label.
2 er day via single-dose dry-powder inhaler of
open-label 18 mug tiotropium, patients were randomised (
3 n HIV-1 infected individuals (SWIFT-C) is an
open-label,
2-cohort clinical trial in which the first c
4 se 4, multicenter, prospectively randomized,
open-label,
24-week study comparing the incidence of pos
5 A multicenter (5 sites),
open-label,
9-month-duration, dose-ranging study was und
6 This randomised, phase 3,
open-label,
active-controlled study was done at 46 sites
7 tients and Methods MATISSE was a randomized,
open-label,
adaptive phase III study.
8 he final analysis from GATSBY, a randomised,
open-label,
adaptive, phase 2/3 study, done at 107 centr
9 a blinded fashion for 12 months, followed by
open-label alendronate in both groups.
10 During the
open-label alendronate period, adjudicated events of ost
11 lic blood pressure (130-149mmHg vs <130mmHg;
open label)
and to antiplatelet treatment (aspirin/clopi
12 es >/=4 [moderate severity] at screening and
open-label baseline).
13 inge-eating days per week for 14 days before
open-label baseline; Clinical Global Impressions-Severit
14 er, parallel-group, prospective, randomized,
open-label,
blinded end point trial, consenting patients
15 cularization (ASTER) study was a randomized,
open-label,
blinded end-point clinical trial conducted i
16 d an international, prospective, randomised,
open-label,
blinded-endpoint trial in adult participants
17 is multicentre, parallel group, superiority,
open-label,
blinded-endpoint, randomised controlled tria
18 Treatment allocation was
open label but endpoints at 12 months were assessed by m
19 The recommended doses of warfarin were
open label,
but the patients and clinicians were blinded
20 Treatment was
open-label,
but investigators assessing primary efficacy
21 intravenously or placebo in combination with
open-label chemotherapy (epirubicin 50 mg/m(2) intraveno
22 A single-site prospective
open-label clinical study with cyclotron-produced sodium
23 This international, randomized,
open-label clinical trial (EUROMAX [European Ambulance A
24 METHODS AND This was a prospective,
open-label clinical trial in 50 patients with coronary a
25 Nonrandomized,
open-label clinical trial initiated in 2015.
26 ucted a multicenter, randomized, controlled,
open-label clinical trial using the Swedish Coronary Ang
27 re enrolled in this randomized, multicenter,
open-label clinical trial, and randomly assigned to RSL
28 In a proof of concept, 6-week,
open-label clinical trial, intranasal theophylline (an e
29 his multicenter, randomized, registry-based,
open-label clinical trial, we enrolled patients with eit
30 hase 3, randomized, controlled, multicenter,
open-label clinical trial.
31 Part B of these randomised, phase 2,
open-label clinical trials enrolled individuals from 15
32 A of these phase 2, randomised, multicentre,
open-label,
clinical trials enrolled participants from 1
33 We did an
open-label cluster-randomised trial in villages in the M
34 We did a phase 4,
open-label,
cluster randomised trial of 22 communities i
35 This
open-label,
cluster, crossover trial was done in two Gha
36 We did an
open-label,
cluster-randomised ring vaccination trial (E
37 We did this
open-label,
cluster-randomised trial (DiRECT) at 49 prim
38 INTERPRETATION: In an
open-label cohort of limited size, brexanolone demonstra
39 In a prospective multicenter
open-label cohort study, 342 patients with abdominal aor
40 ients underwent surgery for DBS and received
open-label continuous stimulation for the entire 1 year
41 Open-label crossover randomized clinical trial conducted
42 After an
open-label dose-escalation study in a pilot safety cohor
43 This was a phase 1,
open-label,
dose-escalating study done at four outpatien
44 This was an
open-label,
dose-escalation phase 1 trial done at two st
45 In this single-centre,
open-label,
dose-escalation phase 1 trial, we recruited
46 In this
open-label,
dose-escalation phase 1-2a study, we gave mo
47 This phase 1b,
open-label,
dose-escalation study assessed the safety, e
48 Phase 1/2a, multicenter,
open-label,
dose-escalation, fellow-eye-controlled study
49 In this phase 2, multicentre,
open-label,
dose-finding study (PACE-MDS), with long-ter
50 ASPIRE consisted of an
open-label,
double-blind phase for 8 weeks and a randomi
51 The ReSource Project was a 9-month
open-label efficacy trial of three, 3-month secularized
52 In the
open-label ELEVATE trial, kidney transplant patients wer
53 e open-label phase (-126.3 minutes at 1-year
open-label end point).
54 r being in prison during the 3 months before
open-label enrolment were more likely to return for at l
55 erapy Trial (SATT), a three-arm, randomised,
open-label,
equivalence trial in five communities in Kar
56 ives included pharmacokinetic assessment and
open-label evaluation of brexanolone response during and
57 as a phase 2, 3-period, randomized sequence,
open-label,
expanded safety and acceptability crossover
58 The
open-label EXTEND study evaluated long-term safety and e
59 controlled study involving 186 patients; an
open label extension study performed after the phase 3.
60 (6-55 years) from 22 centers, with a 2-year,
open-label extension (July 31, 2012-July 31, 2014; exten
61 egrated parent trials) and the first year of
open-label extension (OLE) trials that included a standa
62 1 and 2, reported here) for 12 weeks, and an
open-label extension (part 3).
63 k period could also participate in an 8-week
open-label extension period.
64 Follow-up of patients during the
open-label extension revealed no new safety signals and
65 Phase IV, multicenter,
open-label extension study.
66 This ongoing, randomized
open-label extension trial (OSLER-1) was conducted at 19
67 RAPID-RCT trial were included in this 2-year
open-label extension trial (RAPID-OLE).
68 In an
open-label extension, 115 patients subsequently received
69 were more likely to return for at least one
open-label follow-up visit than those who did not report
70 injected midazolam or were in prison during
open-label follow-up were more likely to be greater than
71 an interim database lock at week 16, and was
open label from week 16 onwards, with no masking of part
72 treatment failure from the run-in period of
open-label inhaled fluticasone, and the treatment period
73 as a phase-3, randomised, active-controlled,
open-label,
international, multicentre trial, done at 10
74 In this randomised,
open-label,
international, phase 3 trial, men with radio
75 Both groups could receive
open-label LAI for 84 additional days.
76 In this
open-label,
masked endpoint, randomised, non-inferiority
77 Patients received
open-label MEDI2070 (210 mg) subcutaneously every 4 week
78 andomly assigned (2:1) to either 24 weeks of
open-label momelotinib 200 mg once a day or BAT (which c
79 In this
open label,
multicenter study conducted over 1-year foll
80 Methods In this
open-label,
multicenter (n = 13), parallel-arm, phase II
81 Single-arm,
open-label,
multicenter clinical study.
82 d C-CREST Part C (PN-3682-011 and -012) were
open-label,
multicenter studies.
83 In an
open-label,
multicenter study, adults >/=65 years of age
84 This phase 3 randomized,
open-label,
multicenter trial compared inolimomab vs usu
85 In this
open-label,
multicenter trial with crossover design, we
86 In a randomized, prospective,
open-label,
multicenter trial, 48 patients with severe C
87 Patients and Methods In an
open-label,
multicenter trial, patients were randomly as
88 VEYOR-II, Part 3 was a partially randomized,
open-label,
multicenter, phase 3 study.
89 We conducted a nonrandomized,
open-label,
multicenter, phase 4 study.
90 Methods This was a single-arm, single-stage,
open-label,
multicenter, phase II trial.
91 We did this single-arm,
open-label,
multicentre phase 3 study at 40 sites in Bel
92 The ARIA study is a randomised,
open-label,
multicentre, active-controlled, parallel-gro
93 This phase 1b,
open-label,
multicentre, dose-escalation study was done
94 This
open-label,
multicentre, phase 1 study was undertaken at
95 In this randomised,
open-label,
multicentre, phase 2 trial, 29 academic medi
96 We did a phase 3, two-group,
open-label,
multicentre, randomised clinical trial at 92
97 6 APDS patients was conducted as a 12-week,
open-label,
multisite, within-subject, dose-escalation s
98 Limitations: The study was
open label,
no inferential statistics were planned, and
99 We did a phase 1/2,
open-label,
non-comparative, dose escalation and expansi
100 We did a multicentre, prospective,
open-label,
non-inferiority randomised clinical trial (S
101 We did a randomised,
open-label,
non-inferiority, parallel-group, multicentre
102 amilial hypercholesterolaemia enrolled in an
open-label,
non-randomised phase 3 trial.
103 In this
open-label,
non-randomised, phase 2 trial, patients aged
104 Multicenter, prospective,
open label,
noncomparative, interventional study.
105 This was a multicenter,
open-label,
noninferiority trial (margin 12%).
106 In this
open-label,
noninferiority trial, we randomly assigned 4
107 In this multicenter,
open-label,
noninferiority trial, we randomly assigned 5
108 In this
open-label,
noninferiority trial, we randomly assigned p
109 DS enrolled in the prospective, multicenter,
open-label,
nonrandomized ML-DS 2006 trial by Nordic Soc
110 METHOD: This 5-year, prospective,
open-label,
nonrandomized, observational registry study
111 e frequently with cumulative exposure during
open-label observation.
112 idate our hypothesis in a phase 2 randomized
open-label parallel-group study in male and female patie
113 The
open-label,
parallel-cohort, dose-escalation, phase I Ch
114 This randomized,
open-label,
parallel-group study included patients aged
115 For this single-centre,
open-label,
parallel-group, randomised controlled trial,
116 The
open-label part A was conducted in the United States, fo
117 rial consisting of an initial 12- to 16-week
open-label period and a 26-week double-blind randomized
118 akathisia (7.7%), and sedation (7.7%) in the
open-label period and mania (11.9% of the placebo group
119 get asenapine dosage was 10 mg b.i.d. in the
open-label period but could be titrated down to 5 mg b.i
120 A total of 549 subjects entered the
open-label period, of whom 253 enrolled in the double-bl
121 After completing the
open-label period, subjects meeting stabilization/stable
122 -time reduction was sustained throughout the
open-label phase (-126.3 minutes at 1-year open-label en
123 Following a 12-week,
open-label phase (dose optimization, 4 weeks [lisdexamfe
124 ost common adverse event with BIIB074 in the
open-label phase (in 13 [19%] of 67 patients), followed
125 In this
open-label phase 1 dose-escalation study conducted at Ba
126 In this multicentre, randomised,
open-label phase 2-3 trial, we recruited patients aged 1
127 We did a randomised,
open-label phase 3 KRISTINE trial in 68 Translational Re
128 SABRINA is a two-stage, randomised,
open-label phase 3 study at 113 centres in 30 countries.
129 NEMO is an ongoing, randomised,
open-label phase 3 study done at 118 hospitals in 26 cou
130 In an
open-label phase 3 trial, we compared first-line nivolum
131 The
open-label phase focused on maintenance of treatment eff
132 Patients and Methods This
open-label phase II study enrolled adults with Ph(+) ALL
133 Patients and Methods This randomized (1:1)
open-label phase II trial compared the efficacy of pazop
134 In this
open-label phase III trial, we evaluated the safety, tol
135 Of the 418 participants enrolled in the
open-label phase of the study, 411 (358 [87.1%] women; m
136 injections for 7 days, followed by a 16-week
open-label phase with canakinumab injections on confirme
137 leted the double-blind phase and entered the
open-label phase, of whom 286 completed 1 year of open-l
138 ed experience of two independently performed
open-label,
phase 1-2 trials (conducted in Sweden and th
139 We did a multicentre, randomised,
open-label,
phase 1/2 study of guadecitabine in cohorts
140 We did an
open-label,
phase 1/2 trial at the National Taiwan Unive
141 as part of the non-randomised, multi-cohort,
open-label,
phase 1b KEYNOTE-012 basket trial.
142 In this
open-label,
phase 1b trial, we recruited patients from 1
143 We did a randomised,
open-label,
phase 2 clinical trial (HPTN 067/ADAPT) of o
144 We did this
open-label,
phase 2 study at 11 hospitals in the USA and
145 This ongoing, multicentre, multicohort,
open-label,
phase 2 study evaluated oral dabrafenib (150
146 We conducted a multicenter,
open-label,
phase 2 study to evaluate the efficacy and s
147 In this
open-label,
phase 2 study, oral acalabrutinib (100 mg tw
148 In this two-cohort, single-arm,
open-label,
phase 2 study, we enrolled patients with sof
149 In this multicenter,
open-label,
phase 2 study, we evaluated the efficacy and
150 was a prospective, multicentre, randomised,
open-label,
phase 2 trial of adult patients (aged >18 ye
151 ficacy and safety data from a single-centre,
open-label,
phase 2 trial, after a median of 83 months f
152 In this ongoing, multicentre,
open-label,
phase 2 trial, we enrolled adults (aged >/=1
153 We did this single-centre,
open-label,
phase 2, multicohort study in the USA.
154 did an international, randomised, multi-arm,
open-label,
phase 3 cooperative group clinical trial of
155 We conducted this multicentre,
open-label,
phase 3 randomised controlled trial (IMvigor
156 (BIG 1-01) is an international, multicentre,
open-label,
phase 3 randomised trial of 5102 women with
157 We did this
open-label,
phase 3 study (SWOG S0819) at 277 sites in t
158 Kids B-LONG was a multicentre,
open-label,
phase 3 study assessing the safety, efficacy
159 This randomised,
open-label,
phase 3 study in untreated patients with sta
160 EMILIA was a randomised, international,
open-label,
phase 3 study of men and women aged 18 years
161 this international, multicentre, randomised,
open-label,
phase 3 study, we enrolled adults (aged >/=1
162 In the randomised, parallel assignment,
open-label,
phase 3 TH3RESA study, progression-free surv
163 We did a randomised,
open-label,
phase 3 trial (OAK) in 194 academic or commu
164 CheckMate 141 was a randomised,
open-label,
phase 3 trial in patients with recurrent or
165 ACCL0431 was a multicentre, randomised,
open-label,
phase 3 trial that enrolled participants at
166 We conducted a multicenter,
open-label,
phase 3 trial to evaluate the efficacy and s
167 In this randomised, controlled,
open-label,
phase 3 trial, we recruited patients aged at
168 In this randomised, controlled,
open-label,
phase 3 trial, we recruited patients with me
169 In this randomised,
open-label,
phase 3 trial, we recruited patients with ne
170 this multicentre, international, randomised,
open-label,
phase 3 trial, we recruited patients with tr
171 In this
open-label,
phase 3, multicentre, international study, a
172 The CONVERT trial was an
open-label,
phase 3, randomised superiority trial.
173 RESPONSE-2 is a randomised,
open-label,
phase 3b study assessing ruxolitinib versus
174 An
open-label,
phase 4 randomized clinical trial designed a
175 was a prospective, randomized, multicenter,
open-label,
phase III noninferiority trial.
176 Patients and Methods In this multicenter,
open-label,
phase III trial, 2,012 women with early TOP2
177 tudy drug dosing during the double-blind and
open-label phases, respectively.
178 he 1315 eligible participants chose to start
open-label PrEP and were followed up for a median of 335
179 We performed an
open-label,
prospective, multicenter study of the effect
180 Methods MITO-8 is an
open-label,
prospective, randomized, superiority trial.
181 nstitutions in 18 countries that included an
open-label randomised arm in which high-dose chemotherap
182 METHODS AND Compass is an
open-label randomised trial of 5-yearly HPV screening ve
183 In this multicentre,
open-label randomised trial, 102 hospitals (Australia [t
184 In this
open-label,
randomised contolled trial, we recruited chi
185 Appendicectomy (CHINA) study, a multicentre,
open-label,
randomised controlled study at 19 specialist
186 ENDEAVOR was a phase 3,
open-label,
randomised controlled trial in patients with
187 We did a pragmatic, multicentre,
open-label,
randomised controlled trial in seven HIV cli
188 We undertook this multicentre,
open-label,
randomised controlled trial in two public ho
189 In this pragmatic, parallel-group,
open-label,
randomised controlled trial, we enrolled adu
190 In this multicentre,
open-label,
randomised controlled trial, we recruited wo
191 We did two prospective,
open-label,
randomised controlled trials assessing iron
192 We initiated this 24 week,
open-label,
randomised controlled, comparative effective
193 The multicentre,
open-label,
randomised phase 3 GOG-0213 trial was done i
194 analysis of additional data from a published
open-label,
randomised trial of second-line ART (EARNEST
195 CALM was an
open-label,
randomised, controlled phase 3 study, done i
196 In this
open-label,
randomised, controlled phase 3 trial done at
197 In this global,
open-label,
randomised, controlled phase 3 trial, we enr
198 uded patients enrolled in the international,
open-label,
randomised, controlled, phase 3 AZURE trial
199 We did an
open-label,
randomised, controlled, two-arm effectivenes
200 We did the multicentre,
open-label,
randomised, parallel, phase 3 SOLE trial in
201 For this
open-label,
randomised, phase 2 selection design trial o
202 tAnGo was an international,
open-label,
randomised, phase 3 superiority trial that e
203 We did an
open-label,
randomised, phase 3 trial of adult patients
204 In this multicentre,
open-label,
randomised, phase 3 trial, we recruited pati
205 In this international,
open-label,
randomised, phase 3, multicentre trial, we e
206 This was a bicentre,
open-label,
randomised, three-arm phase 3 trial done in
207 We conducted an
open-label randomized clinical trial to compare the effi
208 A 12-week, multicenter, outpatient,
open-label randomized clinical trial was conducted at 5
209 ESPAC-4 study, a multicenter, international,
open-label randomized controlled phase III trial of adju
210 ves birth weight.We performed a multicenter,
open-label randomized controlled trial [Maternal and Off
211 In an
open-label randomized crossover study, 19 healthy firefi
212 Purpose Several
open-label randomized studies have suggested that in viv
213 The design of the study was as an
open labeled,
randomized, one treatment, one period, sin
214 This was an
open-label,
randomized (1:1) study (ROPETAR trial).
215 accine (IIV4) was investigated in a phase 3,
open-label,
randomized clinical trial in adults aged >/=
216 An
open-label,
randomized clinical trial with a 5-month fol
217 on, we conducted a prospective, multicenter,
open-label,
randomized phase III trial that compared a b
218 We conducted an
open-label,
randomized, controlled trial to assess the d
219 lanyl-glutamine (AlaGln) in 6 patients in an
open-label,
randomized, crossover pilot trial (EudraCT 2
220 = 16) underwent 4 weeks of sham followed by
open-label rTMS for nonresponders (n = 12).
221 STOP-Uveitis is a randomized,
open-label safety, efficacy, and bioactivity clinical tr
222 Open-label,
safety and efficacy study in patients with H
223 We did a parallel,
open-label single-center randomized controlled trial at
224 e studies had moderate risk of bias (10 were
open-label single-group trials, 11 had limited informati
225 Pragmatic, investigator initiated,
open label,
single site, randomized clinical trial.
226 In this
open-label,
single group, multicentre phase 2 trial, we
227 We did a phase 2,
open-label,
single-arm study at six centres (hospitals a
228 D A prospective, multicenter, nonrandomized,
open-label,
single-arm study of carotid artery stenting
229 In this ongoing,
open-label,
single-arm study that started on December 21
230 This
open-label,
single-arm trial, done in Germany and the UK
231 In this international multicentre,
open-label,
single-arm, first-in-man phase 1 dose-escala
232 We did a multicentre,
open-label,
single-arm, phase 3b study (GARNET) in 20 ho
233 C-SWIFT was an
open-label,
single-center trial in treatment-naive patie
234 This
open-label,
single-centre, phase 1a, dose-escalation tri
235 In this
open-label,
single-group assignment study, with median f
236 nders and 5 were remitters after 6 months of
open-label stimulation.
237 lable controlled trials, was integrated with
open-label studies and case series, along with the exper
238 Previous
open-label studies have shown lower day-to-day variabili
239 In nonrandomized,
open-label studies, a transcatheter interatrial shunt de
240 were pooled from four large, observational,
open-label studies: STRATIFY-2, STRATA, TOP, and TYGRIS.
241 isense oligonucleotide targeting exon 51: an
open label study including 12 patients; a phase 3 random
242 ilization in the 12 patients involved in the
open label study.
243 This phase 2,
open-label study (MAGELLAN-1) evaluated the efficacy and
244 A Phase 2a,
open-label study (NCT01724086) was conducted to assess t
245 We conducted a phase 1
open-label study at ten cancer centres in the USA.
246 This was an
open-label study conducted in the 2012-2013 influenza se
247 ternational, multicentre, two-part, phase 2,
open-label study done at 49 hospitals and cancer centres
248 Twenty-five patients received
open-label study drug.
249 This multicenter,
open-label study evaluated the safety and efficacy of ib
250 We conducted a single-arm,
open-label study in which 15 virologically suppressed HI
251 This multinational,
open-label study included 10 adults with hemophilia B (F
252 This Phase 2,
open-label study included 2 cohorts in New Zealand.
253 S Clinical Trials Group A5175, a randomized,
open-label study of 3 ART regimens among 1571 participan
254 The
Open-Label Study of Long-term Evaluation Against LDL-C (
255 ere randomly assigned (2:1) to switch to the
open-label study regimen or continue the control regimen
256 We performed a multicenter, prospective,
open-label study to determine whether 5 g of intravenous
257 We conducted a phase 2, multicenter,
open-label study to evaluate the efficacy and safety of
258 The aim of this
open-label study was to assess whether this dietary supp
259 This was a phase 3, randomised,
open-label study with a 2 x 2 factorial design.
260 n limitation of this study is that it was an
open-label study with an observed-only control group (no
261 ontrolled study for 16 weeks, followed by an
open-label study with overall 40-week DHA treatment.
262 d, multicohort, multicentre, non-randomised,
open-label study, adults (>/=18 years of age) with previ
263 In this randomised, phase 2b,
open-label study, treatment-naive adults infected with H
264 acrolimus (TacHexal) or Prograf in a 6-month
open-label study.
265 c fibrosis homozygous for F508del-CFTR in an
open-label study.
266 er were enrolled with intent to treat in the
open-label study; 36 completed treatment, had useable da
267 active or sham DBS, followed by 6 months of
open-label subcallosal cingulate DBS.
268 oral semaglutide with placebo (primary) and
open-label subcutaneous semaglutide (secondary) on glyce
269 This multicentre,
open-label substudy was done at 19 sites in seven countr
270 In this randomised, controlled,
open-label,
superiority study, we recruited hospitalised
271 behavioral intervention in conjunction with
open-label TDF/FTC.
272 e trial, participants were offered 1 year of
open-label tenofovir.
273 HRSD17 of 7 following 8 weeks of randomized
open-label treatment ADMs: escitalopram, sertraline or v
274 The sham group was offered
open-label treatment after unblinding.
275 ssigned (1:1:1:1) with a block size of 4, to
open-label treatment to one of four treatment groups: gr
276 er, prospective, randomized, parallel-group,
open-label treatment trial with a blinded end-point eval
277 ients were randomized to receive 24 weeks of
open-label treatment with either 6 or 18 mg of selonsert
278 label phase, of whom 286 completed 1 year of
open-label treatment.
279 In this factorial
open-label trial conducted in Uganda, Zimbabwe, Malawi,
280 ults of a multicenter, phase III, randomized
open-label trial exploring the benefit of adding androge
281 A pilot
open-label trial of arbaclofen suggested similar benefit
282 We conducted an
open-label trial to evaluate the safety, tolerability, a
283 A randomized, controlled,
open-label trial was conducted.
284 For part 2, an
open-label trial was done in which previously vaccinated
285 We did a randomised controlled,
open-label trial with a multi-arm, multi-stage design.
286 Here, we conducted an
open-label trial with PfSPZ Vaccine at a dose of 9.0 x 1
287 In this randomised controlled,
open-label trial, in 29 teaching hospitals and tertiary
288 In a phase 2/3, single-center,
open-label trial, participants from Ontario, Canada, exp
289 In this randomised, phase 3,
open-label trial, patients were screened for eligibility
290 In this single-arm,
open-label trial, we enrolled virologically suppressed,
291 In a multicenter, randomized,
open-label trial, with blinded adjudication of end-point
292 We did two phase 1, randomised,
open-label trials involving healthy adult volunteers.
293 gmatic, multicenter, randomized, controlled,
open-label trials with blinded outcome evaluation: the P
294 In 2 phase 3,
open-label trials, patients with HCV infection who had n
295 Among the 6
open-label (
unblinded) studies, we found that pacing was
296 Phase 1,
open-label,
uncontrolled, dose-escalation study at 5 US
297 We did an
open-label,
uncontrolled, prospective, phase 1 clinical
298 Prospective
open-label,
unilateral single-dose, intravitreal injecti
299 cipants received protocolized treatment with
open-label venlafaxine, up to 300 mg/day for approximate
300 Allocation to cohort 1A and 1B was
open-label,
within cohorts 1A and 2, allocation to DSM26